financetom
Business
financetom
/
Business
/
Stratasys Q3 revenue of $137 mln beats analyst expectations
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Stratasys Q3 revenue of $137 mln beats analyst expectations
Nov 13, 2025 4:58 AM

Overview

* Stratasys ( SSYS ) Q3 revenue of $137 mln beats analyst expectations

* Adjusted EPS of $0.02 beats analyst estimates

* Company reports GAAP net loss due to $33.9 mln non-cash impairment

Outlook

* Stratasys ( SSYS ) sees full-year revenue between $550 mln and $560 mln

* Company expects full-year non-GAAP gross margins of 46.7% to 47.0%

* Stratasys ( SSYS ) anticipates adjusted EBITDA ranging from $30 mln to $32 mln

Result Drivers

* RECURRING REVENUES - Strong recurring revenues contributed to positive adjusted EPS despite GAAP net loss

* STRATEGIC INVESTMENTS - Co investing in technological capabilities and customer relationships to drive growth in high-value applications

* ROBUST CUSTOMER ENGAGEMENT - Customer engagement remains strong across verticals, reinforcing confidence in competitive positioning

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Slight $137 mln $136.60

Revenue Beat* mln (4

Analysts

)

Q3 Beat $0.02 $0.003

Adjusted (4

EPS Analysts

)

Q3 $1.50

Adjusted mln

Net

Income

Q3 $5 mln

Adjusted

EBITDA

Q3 45.30%

Adjusted

Gross

Margin

Q3 $100,000

Adjusted

Operatin

g Income

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the electronic equipment & parts peer group is "buy"

* Wall Street's median 12-month price target for Stratasys Ltd ( SSYS ) is $13.00, about 26.6% above its November 12 closing price of $9.54

* The stock recently traded at 38 times the next 12-month earnings vs. a P/E of 30 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Prelude Therapeutics Says PRT3789 Shows 'Encouraging Signs' in Phase 1 Trial; Shares Fall
Prelude Therapeutics Says PRT3789 Shows 'Encouraging Signs' in Phase 1 Trial; Shares Fall
Sep 13, 2024
11:26 AM EDT, 09/13/2024 (MT Newswires) -- Prelude Therapeutics ( PRLD ) said Friday that interim data from a phase 1 trial of PRT3789 showed encouraging signs of anti-tumor activity in patients with SMARCA4-mutated non-small cell lung cancer and esophageal cancer. We are encouraged by the early clinical activity and emerging safety profile observed to date with PRT3789, said Jane...
Autolus Therapeutics to Amend Lease at Nucleus Manufacturing Facility in UK
Autolus Therapeutics to Amend Lease at Nucleus Manufacturing Facility in UK
Sep 13, 2024
11:20 AM EDT, 09/13/2024 (MT Newswires) -- Autolus Therapeutics ( AUTL ) agreed to amend its lease deal with the landlord of its Nucleus manufacturing facility in Stevenage, UK. The amendment covers up to 18.5 million pounds ($24.3 million) for facility improvements by the landlord, Forge Life Sciences nominees, and an annual rent increase of up to 2.19 million pounds,...
Barclays struggling to sell stake in UK payments business, sources say
Barclays struggling to sell stake in UK payments business, sources say
Sep 13, 2024
* Barclays ( JJCTF ) struggling to sell stake in UK payments arm -sources * Fails to agree on price after private equity talks -sources * Process complicated by takeover of payments partner -sources By Amy-Jo Crowley and Emma-Victoria Farr LONDON, Sept 13 (Reuters) - Barclays ( JJCTF ) is finding it difficult to sell a stake in its British...
What's Going On With Singular Genomics Stock Friday?
What's Going On With Singular Genomics Stock Friday?
Sep 13, 2024
Singular Genomics Systems, Inc. ( OMIC ) shares are trading higher Friday after the company announced it received a non-binding acquisition proposal from Deerfield. The Details: The company announced that it received the offer after the market closed on Thursday. Deerfield offered to buy all outstanding shares that it does not already own for $10 per share. Deerfield also said...
Copyright 2023-2026 - www.financetom.com All Rights Reserved